Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200723 | 0.78 | WDR5 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4770254 | 0.78 | BCHE (0.32) | — | |
| SCHEMBL3527205 | 0.77 | KDM4E (0.33) | ALDH1A1KMT2A | |
| SCHEMBL2475919 | 0.77 | EPHX2 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6349458 | 0.69 | GABRA1 (0.40) | — | |
| SCHEMBL3532281 | 0.61 | SLC6A15 (0.41) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3530779 | 0.61 | ABHD6 (0.44) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4774567 | 0.60 | KDM4E (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL913653 | 0.59 | KDM4E (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL108497 | 0.59 | LMNA (0.38) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098512-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly & Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | APOB, CETP, PCSK9 | MEN1 1183/4885ALDH1A1 2112/4885KMT2A 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.